{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:34:42Z","timestamp":1779147282020,"version":"3.51.4"},"reference-count":107,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.revmed.2024.06.005","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T21:16:53Z","timestamp":1725743813000},"page":"710-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["H\u00e9mophilie acquise\u00a0: quoi de neuf en 2024\u00a0?"],"prefix":"10.1016","volume":"45","author":[{"given":"Herv\u00e9","family":"L\u00e9vesque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Guillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roseline","family":"d\u2019Oiron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ygal","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2024.06.005_bib0540","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1056\/NEJMoa011979","article-title":"The prevalence of proteolytic antibodies against factor VIII in hemophilia A","volume":"346","author":"Lacroix-Desmazes","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2024.06.005_bib0545","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/00000441-194003000-00003","article-title":"Hemorrhagic diathesis with prolonged coagulation time associated with a circulating anticoagulant","volume":"199","author":"Lozier","year":"1940","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.revmed.2024.06.005_bib0550","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.V7.1.20.20","article-title":"Hemorrhagic diathesis due to circulating anticoagulant. Report of case with laboratory observations","volume":"7","author":"Pons","year":"1952","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib0555","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0038-1650169","article-title":"A survey of 215\u00a0non-hemophilic patients with inhibitors to factor VIII","volume":"45","author":"Green","year":"1981","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.06.005_bib0560","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2141.2003.04162.x","article-title":"Acquired haemophilia: review and meta-analysis focused on therapy and prognosis factors","volume":"121","author":"Delgado","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0565","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.2003.04731.x","article-title":"A population based, unselected, consecutive cohort of patients with acquired haemophilia A","volume":"124","author":"Collins","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0570","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1055\/s-0029-1245109","article-title":"Twelve years of experience of acquired haemophilia A: trials and tribulations in south of Austalia","volume":"35","author":"Tay","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.revmed.2024.06.005_bib0575","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.06.005_bib0580","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/hae.12138","article-title":"Outcome of acquired haemophilia in France: the prospective SACHA (surveillance des auto anticorps au cours de l\u2019h\u00e9mophilie acquise) registry","volume":"19","author":"Borg","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0585","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.atherosclerosissup.2012.10.033","article-title":"Long terme outcome of patients with acquired haemophilia\u2013a monocentre interim analysis of 82\u00a0patients","volume":"14","author":"Zeitler","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.revmed.2024.06.005_bib0590","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.revmed.2012.10.367","article-title":"H\u00e9mophilie A acquise. \u00c9tude d\u2019une s\u00e9rie r\u00e9trospective monocentrique de 39\u00a0patients","volume":"34","author":"Graveleau","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.06.005_bib0595","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Pronostic factors for remission of and survival in Acquired Hemophilia A (AHA) results from the GTH-AH 01\/2010\u00a0study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib0600","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MBC.0000000000000582","article-title":"Assessment of acquired haemophilia patient demographics in the United States: the Hemostasis And Thrombosis Research Society Registry","volume":"27","author":"Kessler","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.revmed.2024.06.005_bib0605","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jfma.2013.01.006","article-title":"A study of 65\u00a0patients with acquired haemophilia in Taiwan","volume":"114","author":"Huang","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.revmed.2024.06.005_bib0610","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.16128","article-title":"Outcome of CARE: a 6-year national registry of acquired haemophilia A in China","volume":"187","author":"Sun","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0615","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.26009","article-title":"Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study","volume":"96","author":"Schep","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0620","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1111\/hae.14370","article-title":"Clinical characteritics and prognostic factors of acquired haemophilia A in Korea","volume":"27","author":"Hyun","year":"2021","journal-title":"Hemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0625","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/bloodadvances.2021004626","article-title":"Management of acquired hemophilia A: results from the Spanish registry","volume":"5","author":"Mingot-Castellano","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2024.06.005_bib0630","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom haemophilia centre doctors\u2019 organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib0635","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.18611","article-title":"Acquired haemophilia A in four north european countries: survey of 181\u00a0patients","volume":"201","author":"Lindahl","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0640","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12185-022-03467-w","article-title":"ORIHIME study: real-world treatments patterns and clinical outcomes of 338\u00a0patients with acquired hemophilia A from a japanese administrative database","volume":"117","author":"Ogawa","year":"2023","journal-title":"Intern J Hematol"},{"issue":"5","key":"10.1016\/j.revmed.2024.06.005_bib0645","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/hae.14845","article-title":"Acquired haemophilia A: a 15-year population-based review of incidence rate, patient demographics and treatment outcome","volume":"29","author":"Tian","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0650","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.thromres.2023.11.025","article-title":"Characteristics and outcomme of a territory-wide cohort study of patients with acquired hemiphilia A in Hong Kong","volume":"233","author":"Sin","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.revmed.2024.06.005_bib0655","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1111\/hae.14149","article-title":"The rising incidence of acquired haemophilia A in Germany","volume":"27","author":"Tiede","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0660","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune check point inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2024.06.005_bib0665","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating factor VIII: recent progress","volume":"10","author":"Lacroix-Desmares","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0670","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1073\/pnas.89.9.3795","article-title":"Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals","volume":"89","author":"Algiman","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.revmed.2024.06.005_bib0675","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major difference between neutralizing and nonneutralizing antibodies in human","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib0680","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2015-09-672774","article-title":"Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"127","author":"Tiede","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib0685","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00277-009-0887-3","article-title":"Acquired haemophilia caused by non-haemophilic factor VIII gene variants","volume":"89","author":"Tiede","year":"2010","journal-title":"Ann Hematol"},{"issue":"suppl. 3","key":"10.1016\/j.revmed.2024.06.005_bib0690","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02259.x","article-title":"Genetics markers in acquired haemopjilia","volume":"16","author":"Oldenburg","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0695","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41577-020-00454-2","article-title":"Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey","volume":"21","author":"El Tanbouly","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0700","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3389\/fimmu.2018.01201","article-title":"CD8+, HLADR+ regulatory T cells change with aging: they increase in number, but lose checkpoint inhibitory molecules and suppressive function","volume":"9","author":"Lukas Yani","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0705","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.imlet.2022.01.005","article-title":"Immune system aging and rthe aging-related diseases in the Covid-19\u00a0era","volume":"243","author":"Witkowski","year":"2022","journal-title":"Immunol Lett"},{"key":"10.1016\/j.revmed.2024.06.005_bib0710","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2010-07-296103","article-title":"Proteolytic antibodies active factor IX in patients with acquired hemophilia","volume":"117","author":"Wootla","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib0715","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2011.08890.x","article-title":"Do proteolytic antibodies complete the panoply of the autoimmune response in acquired hemophilia A?","volume":"156","author":"Mahendra","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0720","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2022008071","article-title":"Targets of autoanibodies in acquired hemophilia A are no restricted to factor VIII: data from the GTH-HA 01\/2010\u00a0study","volume":"7","author":"Oleshko","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2024.06.005_bib0725","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/j.1538-7836.2012.04850.x","article-title":"The IgG immune response in post-partum acquired hemophilia A targets mainly the domain A1a1\u00a0of FVIII","volume":"10","author":"Lapalud","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.06.005_bib0730","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib0735","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommandations of the diagnosis and treatment of patients with acquired haemophilia","volume":"94","author":"Huth-K\u00fchne","year":"2009","journal-title":"Haemotologica"},{"key":"10.1016\/j.revmed.2024.06.005_bib0740","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/hae.13752","article-title":"The factor VIII:C\/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: a retrospective cohort study","volume":"25","author":"Trossaert","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0745","doi-asserted-by":"crossref","first-page":"e5232","DOI":"10.1097\/MD.0000000000005232","article-title":"Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: a retrospective single-center study","volume":"95","author":"Vautier","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2024.06.005_bib0750","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0755","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2024.06.005_bib0760","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jbspin.2014.12.003","article-title":"Acquired hemophilia possibly induced by etarnercept in a patient with rhumatoid arthritis","volume":"82","author":"Bance","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2024.06.005_bib0765","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/RHU.0b013e31823ee3cd","article-title":"Fatal acquired hemophilia A in a patient with rheumatoid arthritis treated with adalimumab","volume":"18","author":"Arthanari","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0770","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jbspin.2015.04.003","article-title":"Acquired hemophilia rheumatoid arthritis and TNF alpha antagonists. Comment on the article \u201cacquired hemophilia possibly induced by etarnercept in a patient with rhumatoid arthritis, by Banse et al. Joint Bone Spine 2015; 82: 200-2\u201d","volume":"82","author":"Brinster","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2024.06.005_bib0775","doi-asserted-by":"crossref","first-page":"e22926","DOI":"10.1097\/MD.0000000000022926","article-title":"Acquired hemophilia A in a woman with sytemic lupus erythematosus","volume":"99","author":"Shen","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2024.06.005_bib0780","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/bjd.20953","article-title":"A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic features","volume":"186","author":"Barranca","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0785","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/hae.13355","article-title":"Acquired haemophilia in cancer: a systematic and critical literature review","volume":"24","author":"Napolitano","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0790","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.revmed.2015.09.004","article-title":"H\u00e9mophilie A acquise et h\u00e9mopathies lympho\u00efdes\u00a0: revue de la litt\u00e9rature","volume":"36","author":"Le Cam-Duchez","year":"2015","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.06.005_bib0795","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1111\/hae.14632","article-title":"Immune check point inhibitor-induced acquired hemophilia:a pharmacovigilance analysis of the FDA adverse event reporting system","volume":"28","author":"Moore","year":"2022","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.revmed.2024.06.005_bib0800","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MBC.0000000000001244","article-title":"Acquired bleeding disorders secondary to immune check point inhibitors: a case report and systematic review literature","volume":"34","author":"Archibald","year":"2023","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.revmed.2024.06.005_bib0805","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.20390","article-title":"Acquired hemophilia A: a concise review","volume":"80","author":"Francini","year":"2005","journal-title":"Am J Haematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0810","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s13300-019-0609-3","article-title":"Acquired hemophilia A associated with dipeptidyl peptidase-4\u00a0for the treatment of type 2\u00a0diabetes mellitus: a single-center case series in Japan","volume":"10","author":"Yamasaki","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.revmed.2024.06.005_bib0815","first-page":"RA55","article-title":"Drug induced anti FVIII antibodies: a systematic review","volume":"13","author":"Franchini","year":"2007","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.revmed.2024.06.005_bib0820","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/hae.14692","article-title":"Drug-associated acquired hemophilia: an analysis based on 185\u00a0cases from the WHU pharmacovigilance database","volume":"29","author":"Konstantinov","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0825","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1111\/hae.14632","article-title":"Immune checkpoint inhibitor-induced acquired haemophilia: a pharmacovigilance analysis of the FDA adverse event reporting system","volume":"28","author":"Moore","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0830","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.revmed.2022.08.009","article-title":"Life threatening chlorpromazine-induced acquired haemophilia A in a patient with a cavernous malformation involving the medulla oblongata","volume":"43","author":"Stammler","year":"2022","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.06.005_bib0835","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s13300-019-0609-3","article-title":"Acquired hemophilia A associated with dipeptidyl peptidase-4\u00a0inhibitors for the treatment of type 2\u00a0diabetes mellitus: a single-center case series in Japan","volume":"10","author":"Yamasaki","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.revmed.2024.06.005_bib0840","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/jth.15421","article-title":"The statistical risk of diagnosing coincidental acquired hemophilia A associated with mRNA Covid-19\u00a0vaccines","volume":"19","author":"Cittore","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.06.005_bib0845","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/jth.15665","article-title":"Investigating potential mechanisms underlying FVIII inhibitors in acquired hemophilia A associated with mRNA Covid-19\u00a0vaccines","volume":"20","author":"Hirsiger","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.06.005_bib0850","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0042-1754389","article-title":"Investigating a signal of acquired hemophilia associated with Covid-19\u00a0vaccination. A systematic cases review","volume":"49","author":"Franchini","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.revmed.2024.06.005_bib0855","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.revmed.2021.07.003","article-title":"Characterizing hospital pathway for the care of acquired hemophilia in France using comprehensive national health data","volume":"43","author":"Guillet","year":"2022","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.06.005_bib0860","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1471-0528.2012.03469.x","article-title":"Pregnancy-associated acquired haemophilia A: results from the european acquired haemophilia (EACH2) registry","volume":"119","author":"Tengborn","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.revmed.2024.06.005_bib0865","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1471-0528.2003.01535.x","article-title":"Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice","volume":"110","author":"Baudo","year":"2003","journal-title":"BJOG"},{"key":"10.1016\/j.revmed.2024.06.005_bib0870","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.revmed.2022.04.012","article-title":"H\u00e9mophilie acquise et grossesse\u00a0: une approche forcement multidisciplinaire","volume":"43","author":"L\u00e9vesque","year":"2022","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.06.005_bib0875","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/bcp.14227","article-title":"Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: a population-based nested case-control study","volume":"86","author":"Zhang","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0880","doi-asserted-by":"crossref","first-page":"791285","DOI":"10.3389\/fnagi.2022.791285","article-title":"Major bleeding risk in patients with non-valvular atrial fibrillation concurrently taking direct oral anticoagulants and antidepressants","volume":"14","author":"Chang","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.revmed.2024.06.005_bib0885","doi-asserted-by":"crossref","first-page":"39580","DOI":"10.52965\/001c.39580","article-title":"Selective serotonin reuptake inhibitors and associated bleeding risks: a narrative and clinical review","volume":"10","author":"Edinoff","year":"2022","journal-title":"Health Psychol Res"},{"key":"10.1016\/j.revmed.2024.06.005_bib0890","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.revmed.2020.10.382","article-title":"Ulc\u00e8res n\u00e9crotiques et purpuriques des membres inf\u00e9rieurs r\u00e9v\u00e9lant un scorbut\u00a0: \u00e0 propos de deux observations","volume":"42","author":"Guellich","year":"2021","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.06.005_bib0895","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.revmed.2017.01.008","article-title":"Syndrome de Gardner et Diamond\u00a0: \u00e0 propos d\u2019un cas chez un homme jeune et revue de la litt\u00e9rature","volume":"38","author":"Henneton","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.06.005_bib0900","first-page":"53","article-title":"Groupe de recherche et d\u2019\u00e9tudes de l\u2019h\u00e9mophilie du centre et de l\u2019Ouest\u202f; le traitement de l\u2019hemophilie","year":"2002","journal-title":"Med Sci Flammarion"},{"key":"10.1016\/j.revmed.2024.06.005_bib0905","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2516.2007.01474.x","article-title":"Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal","volume":"13","author":"Sumner","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0910","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-018-3372-z","article-title":"Lessons from a systematic review of the effectiveness of recombinant factor VIIa in acquired haemophilia","volume":"97","author":"Tiede","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0915","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2516.2003.00856.x","article-title":"Tretment of acquired hemophilia with factor inhibitor bypassing activity","volume":"10","author":"Sallah","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0920","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjh.15175","article-title":"Activated prothrombin complex concentrate (FEIBA\u00ae) in acquired haemophilia A. A large multicentre italina Study\u00a0\u2013\u00a0the FAIR registry","volume":"184","author":"Zanon","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0925","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/hae.12574","article-title":"FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre french \u00ab\u00a0FEIBA dans l\u2019h\u00e9mophilie A acquise (FEIHBAC)\u00a0\u00bb registry","volume":"21","author":"Borg","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0930","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11239-018-1750-y","article-title":"Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR registry","volume":"47","author":"Pasca","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.revmed.2024.06.005_bib0935","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0940","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood.V86.2.797.bloodjournal862797","article-title":"A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin","volume":"86","author":"Schwartz","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib0945","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1756-0500-3-161","article-title":"Consensus recommendations for the diagnosis and treatment of acquired hemophilia A","volume":"3","author":"Collins","year":"2010","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.revmed.2024.06.005_bib0950","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/hae.13844","article-title":"Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: a global expert consensus statment","volume":"25","author":"Tiede","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0955","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with treatment of acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.06.005_bib0960","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/hae.14664","article-title":"Emicizumab for the treatment of acquired hemophilia A: retrospective review of a single-institution experience","volume":"29","author":"Chen","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib0965","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib0970","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/hae.14809","article-title":"Emicizumab for acquired haemophilia A: a case series","volume":"29","author":"Engelen","year":"2023","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.revmed.2024.06.005_bib0975","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2\u00a0study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0980","first-page":"279","article-title":"Bleeding and response to haemostatic therapy in acquired haemophilia A: results from the GTH-AH 01\/2010\u00a0study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib0985","first-page":"245","article-title":"Acquired haemophilia A: Italian consensus recommendations on diagnosis, general management and treatement of bleeding","volume":"20","author":"Coppola","year":"2022","journal-title":"Blood Transfus"},{"key":"10.1016\/j.revmed.2024.06.005_bib0990","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2141.1981.00635.x","article-title":"Corticosteroid therapy for acquired factor VIII:C inhibitors","volume":"48","author":"Spero","year":"1981","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib0995","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1055\/s-0038-1649664","article-title":"A prospective randomised trial of prednisolone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies","volume":"70","author":"Green","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.06.005_bib1000","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for Acquired Haemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib1010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2024.03.012","article-title":"Cyclophosphamide versus rituximab for eradicating inhibitors in acquired hemophilia A. The CREHA study: a randomized open-label trial in 108\u00a0patients","volume":"237","author":"L\u00e9vesque","year":"2024","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.revmed.2024.06.005_bib1015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ajh.27128","article-title":"Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: a multicenter, open-label, randomized noninferiority trial","volume":"99","author":"Wang","year":"2024","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.revmed.2024.06.005_bib1005","first-page":"CD011907","article-title":"Rituximab for eradicating inhibitors in people with acquired haemophilia A","volume":"8","author":"Remminghton","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2024.06.005_bib1020","first-page":"e59","article-title":"Mycophenolate mofetil as a adjunctive therapy in acquired hemophilia A","volume":"25","author":"Obaji","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib1025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1365-2516.2012.02772.x","article-title":"Acquired haemophilia A: first line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up","volume":"18","author":"Pardos-Gea","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib1030","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.2022016873","article-title":"Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen","volume":"140","author":"Simon","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2024.06.005_bib1035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ejh.13708","article-title":"A low-dose rituximab regimen for the first line treatment of acquired hemophilia A","volume":"108","author":"Hunt","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib1040","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2217\/fon-2022-0112","article-title":"Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review","volume":"18","author":"Davies","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.revmed.2024.06.005_bib1045","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jtha.2023.03.010","article-title":"Anti-CD 38\u00a0antibody for refractory acquired hemophilia A","volume":"21","author":"Liu","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2024.06.005_bib1050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/hae.14233","article-title":"Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: a systematic literature review","volume":"27","author":"Dewarrat","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.revmed.2024.06.005_bib1055","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjh.19285","article-title":"Acquired haemophilia A in paediatric patients: a retrospective French cohort of eight cases","volume":"204","author":"Mouthon","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2024.06.005_bib1060","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/pbc.22657","article-title":"Acquired hemophilia in pediatrics: a systematic review","volume":"55","author":"Franchini","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.revmed.2024.06.005_bib1065","doi-asserted-by":"crossref","first-page":"e29530","DOI":"10.1002\/pbc.29530","article-title":"Pediatric acquired factor VIII deficiency presenting as hemarthrosis","volume":"69","author":"Daigh","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.revmed.2024.06.005_bib0535","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/hae.13685","article-title":"Relapse pattern and long-term outcomes in subjects with acquired haemophilia A","volume":"25","author":"Mizrahi","year":"2019","journal-title":"Haemophilia"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324006660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324006660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T11:38:10Z","timestamp":1730979490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866324006660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":107,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0248866324006660"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2024.06.005","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"H\u00e9mophilie acquise\u00a0: quoi de neuf en 2024\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2024.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}